Evidence map›Paper›PMID 28673974›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2017

MRG15-mediated tethering of PALB2 to unperturbed chromatin protects active genes from genotoxic stress.

Jean-Yves Bleuyard, Marjorie Fournier, Ryuichiro Nakato, Anthony M Couturier, Yuki Katou, Christine Ralf, Svenja S Hester, Daniel Dominguez, Daniela Rhodes, Timothy C Humphrey and 2 more

Open access · bronzeAbstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 60 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 4 countries.

Jean-Yves BleuyardSir William Dunn School of Pathology, University of Oxford, Oxford, OX1 3RE, United Kingdom.
Marjorie FournierSir William Dunn School of Pathology, University of Oxford, Oxford, OX1 3RE, United Kingdom.
Ryuichiro NakatoResearch Center for Epigenetic Disease, Graduate School of Frontier Sciences, The University of Tokyo, Tokyo 113-0032, Japan.
Anthony M CouturierSir William Dunn School of Pathology, University of Oxford, Oxford, OX1 3RE, United Kingdom.
Yuki KatouResearch Center for Epigenetic Disease, Graduate School of Frontier Sciences, The University of Tokyo, Tokyo 113-0032, Japan.
Christine RalfSir William Dunn School of Pathology, University of Oxford, Oxford, OX1 3RE, United Kingdom.
Svenja S HesterAdvanced Proteomics Facility, Department of Biochemisty, University of Oxford, Oxford, OX1 3QU, United Kingdom.
Daniel DominguezDepartment of Biology, Massachusetts Institute of Technology, Cambridge, MA 02139-4307.
Daniela RhodesNTU Institute of Structural Biology, Nanyang Technological University, 636921 Singapore.
Timothy C HumphreyCancer Research UK/Medical Research Council Oxford Institute for Radiation Oncology, Department of Oncology, University of Oxford, Oxford, OX3 7DQ, United Kingdom.
Katsuhiko ShirahigeResearch Center for Epigenetic Disease, Graduate School of Frontier Sciences, The University of Tokyo, Tokyo 113-0032, Japan.
Fumiko EsashiSir William Dunn School of Pathology, University of Oxford, Oxford, OX1 3RE, United Kingdom; fumiko.esashi@path.ox.ac.uk.ORCID 0000-0003-0902-2364
University of Oxford · GBThe University of Tokyo · JPCancer Research UK · GBMassachusetts Institute of Technology · USNanyang Technological University · SG

Funding

Medical Research Council MC-PC-12001Medical Research Council MC_PC_12001Medical Research Council MC_PC_12003Medical Research Council MC_U142784382Medical Research Council MC_UU_00001/4Wellcome Trust 101009
6 · The paper itself

Abstract

The partner and localiser of BRCA2 (PALB2) plays important roles in the maintenance of genome integrity and protection against cancer. Although PALB2 is commonly described as a repair factor recruited to sites of DNA breaks, recent studies provide evidence that PALB2 also associates with unperturbed chromatin. Here, we investigated the previously poorly described role of chromatin-associated PALB2 in undamaged cells. We found that PALB2 associates with active genes through its major binding partner, MRG15, which recognizes histone H3 trimethylated at lysine 36 (H3K36me3) by the SETD2 methyltransferase. Missense mutations that ablate PALB2 binding to MRG15 confer elevated sensitivity to the topoisomerase inhibitor camptothecin (CPT) and increased levels of aberrant metaphase chromosomes and DNA stress in gene bodies, which were suppressed by preventing DNA replication. Remarkably, the level of PALB2 at genic regions was frequently decreased, rather than increased, upon CPT treatment. We propose that the steady-state presence of PALB2 at active genes, mediated through the SETD2/H3K36me3/MRG15 axis, ensures an immediate response to DNA stress and therefore effective protection of these regions during DNA replication. This study provides a conceptual advance in demonstrating that the constitutive chromatin association of repair factors plays a key role in the maintenance of genome stability and furthers our understanding of why PALB2 defects lead to human genome instability syndromes.

Indexed as

DNA DamageBRCA2 ProteinCell Line, TumorChromatinChromosomesDNA RepairDNA ReplicationFanconi Anemia Complementation Group N ProteinGenome, HumanHEK293 CellsHeLa CellsHistone-Lysine N-MethyltransferaseHumansInhibitory Concentration 50MutationProtein BindingBRCA2 ProteinBRCA2 protein, humanChromatinFanconi Anemia Complementation Group N ProteinHistone-Lysine N-MethyltransferaseMORF4L1 protein, humanPALB2 protein, humanSETD2 protein, humanTranscription FactorsTumor Suppressor ProteinsDNA replicationMRG15PALB2SETD2transcription

Identifiers

PMID28673974
PMCPMC5530651
OpenAlexW2731075639

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.